Trends and projections of inflammatory bowel disease at the global, regional and national levels, 1990-2050: a bayesian age-period-cohort modeling study.

BACKGROUND: Inflammatory bowel disease (IBD) is a global health concern with varying levels and trends across countries and regions. Understanding these differences is crucial for effective prevention and treatment strategies. METHODS: Using data from the 2019 Global Burden of Disease study, we examine IBD incidence, mortality, and disability-adjusted life years (DALYs) rates in 198 countries from 1990 to 2019. To assess changes in the burden of IBD, estimated annual percentage changes (EAPC) were calculated, and a Bayesian age-period-cohort model was used to predict the future 30-year trends of IBD. RESULTS: In 2019, there were 405,000 new IBD cases globally (95% uncertainty interval (UI) 361,000 to 457,000), with 41,000 deaths (95% UI 35,000 to 45,000) and 1.62million DALYs (95% UI 1.36-1.92million). The global age-standardized incidence rate in 2019 was 4.97 per 100,000 person-years (95% UI 4.43 to 5.59), with a mortality rate of 0.54 (95% UI 0.46 to 0.59) and DALYs rate of 20.15 (95% UI 16.86 to 23.71). From 1990 to 2019, EAPC values for incidence, mortality, and DALYs rates were - 0.60 (95% UI - 0.73 to - 0.48), - 0.69 (95% UI - 0.81 to - 0.57), and - 1.04 (95% UI - 1.06 to - 1.01), respectively. Overall, the burden of IBD has shown a slow decline in recent years. In SDI stratification, regions with higher initial SDI (high-income North America and Central Europe) witnessed decreasing incidence and mortality rates with increasing SDI, while regions with lower initial SDI (South Asia, Oceania, and Latin America) experienced a rapid rise in incidence but a decrease in mortality with increasing SDI. Predictions using a Bayesian model showed lower new cases and deaths from 2020 to 2050 than reference values, while the slope of the predicted incidence-time curve closely paralleled that of the 2019 data. CONCLUSION: Increasing cases, deaths, and DALYs highlight the sustained burden of IBD on public health. Developed countries have stabilized or declining incidence rates but face high prevalence and societal burden. Emerging and developing countries experience rising incidence. Understanding these changes aids policymakers in effectively addressing IBD challenges in different regions and economic contexts.

[Inhibitory effect of 5-aminoisoquinolinone on PARP activity in colon carcinoma cell line HT-29].

BACKGROUND & OBJECTIVE: 5-Aminoisoquinolinone(5-AIQ),a poly(adenosine 5'-diphosphate ribose) polymerase (PARP) inhibitor, plays an important role in inflammation, but its role in tumors is unclear. This study was to investigate the biological role of 5-AIQ-induced PARP inhibition in colon carcinoma cell line HT-29. METHODS: The expression of poly(adenosine 5'-diphosphate ribose) (PAR) and co-expression of PAR with P-selectin and intercellular adhesion molecule-1 (ICAM-1) in 45 specimens of colorectal carcinoma and 10 specimens of adjacent normal colorectal mucosa were detected by SP immunohistochemistry and double immunofluorescence staining. After treatment of 5-AIQ, the adhesion of colon carcinoma cell line HT-29 to human umbilical vein endothelial cells (HUVEC) was detected by adhesion experimentû the expression of PAR, P-selectin, and ICAM-1 in HT-29 cells was detected by SP immunohistochemistry. RESULTS: The positive rate of PAR was significantly higher in colorectal carcinoma than in control colorectal mucosa (77.8% vs. 10.0%, P < 0.05), and higher in colorectal carcinomas with metastasis than in colorectal carcinomas without metastasis (86.7% vs. 60.0%). PAR expression was correlated to P-selectin and ICAM-1 expression. Cell adhesion rate was significantly lower in 100, 300, and 500 mumol/L 5-AIQ-treated HT-29 cells than in control cells (55.79%, 46.31%, and 39.77% vs. 100%, P < 0.05). The protein levels of PAR, P-selectin, and ICAM-1 were significantly lower in 5-AIQ-treated HT-29 cells than in control cells (1.41+/-0.12 vs. 2.61+/-0.10, 1.57+/-0.13 vs. 2.73+/-0.16, 1.23+/-0.13 vs. 2.30+/-0.12, P < 0.05). CONCLUSIONS: PARP activity is enhanced in colorectal carcinoma. PARP inhibitor 5-AIQ can inhibit the adhesion of HT-29 cells to HUVECs, and the expression of PAR, P-selectin, and ICAM-1 in HT-29 cells.